NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 58 resultados LastUpdate Última actualización 28/03/2017 [14:18:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   Mostrar por página


ANTI-NEOPLASTIC COMPOUNDS AND METHODS TARGETING QSOX1

NºPublicación: WO2017048712A1 23/03/2017

Solicitante:
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIV [US]
MAYO FOUNDATION [US]

Resumen de: WO2017048712A1

Compounds and methods involving inhibition of the enzymatic activity of QSOX1 (Fig. 13). The compounds and methods can be used in treatment of neoplastic cells, for example, to suppress tumor growth and invasion in a variety of cancers, including but not limited to myeloma and cancers of the breast, kidney, and pancreas.



traducir


 

Oligonucleotide Compositions and Methods for Treating Acute Lymphoblastic Leukemia

NºPublicación: US2017080009A1 23/03/2017

Solicitante:
GMEINER WILLIAM H [US]
PARDEE TIMOTHY S [US]

Resumen de: US2017080009A1

F10 is an oligonucleotide based on the thymidylate synthase (TS) inhibitory 5-fluorouracil (5-FU) metabolite, 5-fluoro-2′-deoxyuridine-5′-O-monophosphate. The activity of F10 against preclinical ALL models was determined. F10 treatment resulted in robust induction of apoptosis that could not be equaled by 100 fold more 5-FU. F10 was more potent than Ara-C and doxorubicin against a panel of murine and human ALL cells with an average IC50 value of 1.48 nM (range 0.07 to 5.4 nM). F10 was more than 1000 times more potent than 5-FU. In vivo, F10 treatment resulted in a significant increase in survival in 2 separate syngeneic ALL mouse models and 3 separate xenograft models. F10 also protected mice from leukemia-induced weight loss. In ALL cells made resistant to Ara-C F10 remained highly active in vitro and in vivo. Using labeled F10, it was determined that uptake by the ALL cell lines DG75 and SUP-B15 was rapid and had a profound temperature dependence. Both cell lines demonstrated increased uptake compared to normal, murine, lineage-depleted marrow cells. Consistent with this decreased uptake, F10 treatment did not alter the ability of human HSCs to engraft in immunodeficient mice.



traducir


 

A HUMANIZED MOUSE MODEL OF DE NOVO HUMAN ACUTE MYELOID LEUKEMIA WITH A MATCHING HUMAN IMMUNE SYSTEM

NºPublicación: WO2017049002A1 23/03/2017

Solicitante:
MASSACHUSETTS INST TECHNOLOGY [US]

Resumen de: WO2017049002A1

Method of producing a non-human mammal that is a model for human NPM1c+ acute myeloid leukemia are described, as well as a viral vector useful in producing the non-human mammal. Also described are methods of identifying one or more agents that can be used to treat human acute myeloid leukemia using the non-human mammals.



traducir


 

SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS

NºPublicación: US2017080103A1 23/03/2017

Solicitante:
SYNTHON BIOPHARMACEUTICAL B V [NL]

Resumen de: US2017080103A1

The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.



traducir


 

PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER

NºPublicación: WO2017046604A1 23/03/2017

Solicitante:
REDX PHARMA PLC [GB]

Resumen de: WO2017046604A1

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.



traducir


 

T-CELL RECEPTOR (TCR) TARGETING THERAPIES FOR IMMUNE-MEDIATED ADVERSE DRUG REACTIONS (ADRs) AND OTHER CONDITIONS

NºPublicación: WO2017049159A1 23/03/2017

Solicitante:
LEDEBUR JR HARRY C [US]

Resumen de: WO2017049159A1

The present invention provides methods and compositions for treating immune mediated adverse drug reactions using anti-αβ TCR antibodies and fragments thereof. The adverse drug reactions treated according to the invention include severe cutaneous adverse reactions, idiosyncratic liver injury, and idiopathic drug-induced liver disease. The invention also provides methods and compositions for treating conditions such as epidermolysis bullosa, pemphigus vulgaris, cutaneous T cell lymphoma, and Goodpasture syndrome where T cells play a significant role. Anti-αβ TCR antibodies used in the treatment methods of the invention include T10B9, MEDI-500 and TOL101.



traducir


 

ANTI-S100A8 FOR TREATING LEUKEMIA

NºPublicación: WO2017045070A1 23/03/2017

Solicitante:
UNIV LAVAL [CA]

Resumen de: WO2017045070A1

The present description relates to an anti-S1008 protein for treating leukemia. More specifically, is disclosed anti-S100A8 antibody that specifically binds to a portion of S100A8 protein and/or a S100A8/S100A9 heterodimer for treating leukemia.



traducir


 

Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-PD1 or anti-PDL1 monoclonal antibody

NºPublicación: AU2015315435A1 23/03/2017

Solicitante:
CELGENE CORP

Resumen de: AU2015315435A1

The present disclosure provides methods of treating diseases or disorders with oral cytidme analogs (e.g., 5-azacyddme) in combination with anti-PDl/anti-PDLl antibodies (e.g., pembrolizumab or durvalumab). The diseases or disorders include, but are not limited to, relapsed or refractory myelodysplastic syndromes, acute myeloid leukemia, ovarian cancer, or non-small cell lung cancer.



traducir


 

Tetrahydronaphthalene derivatives that inhibit Mcl-1 protein

NºPublicación: AU2015308735A1 23/03/2017

Solicitante:
AMGEN INC

Resumen de: AU2015308735A1

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, (I) and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.



traducir


 

LYMPHOMA PROGNOSTIC METHODS AND KITS

NºPublicación: US2017081726A1 23/03/2017

Solicitante:
REGENTS OF THE UNIV OF MINNESOTA [US]

Resumen de: US2017081726A1

This disclosure describes, in one aspect, a method that, in general, includes analyzing a tumor tissue sample from a subject for expression of at least two biomarkers, wherein a predetermined ratio of expression of the at least two biomarkers identifies the tumor tissue sample as coming from a subject having a particular subtype of lymphoma; and identifying the subject as having a particular subtype of lymphoma.



traducir


 

FUSION PROTEIN INHIBITING TACI-BAFF COMPLEX FORMATION AND PREPARATION METHOD THEREFOR AND USE THEREOF

NºPublicación: US2017081387A1 23/03/2017

Solicitante:
SHANGHAI KANDA BIOTECHNOLOGY CO LTD [CN]
SHANGHAI CELGEN BIO-PHARMACEUTICAL CO LTD [CN]

Resumen de: US2017081387A1

The present invention provides a fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof. Specifically, the fusion protein of the present invention is of high biological activity for blocking BAFF/APPRIL, and may significantly lower the serum IgM concentration in normal Balb/c mice as well as the serum IgM and IgE concentration in C57/B6 mice with asthma. The TACI-Fc fusion protein of the present invention may be used in the treatment of autoimmune diseases, including asthma, systemic lupus eythematosus and rheumatoid arthritis, etc., and may also be used in the treatment of B cell enrichment-related diseases, including multiple myeloma, chronic lymphocytic leukemia, macroglobulinemia and plasmacytic leukemia, etc.



traducir


 

Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor

NºPublicación: US2017079981A1 23/03/2017

Solicitante:
PHARMACYCLICS LLC [US]

Resumen de: US2017079981A1

Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.



traducir


 

METHODS FOR CHARACTERIZING AND TREATING ACUTE MYELOID LEUKEMIA

NºPublicación: US2017080102A1 23/03/2017

Solicitante:
IMMUNOGEN INC [US]

Resumen de: US2017080102A1

The invention features methods for characterizing and treating acute myeloid leukemia (AML) (e.g., newly diagnosed, relapsed, and refractory AML) in a subject using immunoconjugates of the invention. In one aspect, the invention generally features a method of treating acute myeloid leukemia in a subject (e.g., a human), the method involving administering an effective amount of an immunoconjugate to a pre-selected subject, where the immunoconjugate contains a humanized or chimeric antibody or fragment conjugated to a cytotoxic benzodiazepine dimer compound via a cleavable disulfide linker.



traducir


 

MONITORING LYMPHOID NEOPLASM STATUS USING CLONOTYPE PROFILES

NºPublicación: EP3144673A1 22/03/2017

Solicitante:
ADAPTIVE BIOTECHNOLOGIES CORP [US]

Resumen de: EP3144673A1

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.



traducir


 

TREATING CHRONIC MYELOGENOUS LEUKEMIA (CML)

NºPublicación: EP3143166A2 22/03/2017

Solicitante:
UNIV MASSACHUSETTS [US]

Resumen de: WO2015175846A2

Methods for treating chronic myeloid leukemia (CML), e.g., BCR-ABL inhibitor imatinib mesylate (IM)-resistant CML, using combination treatments, e.g., combined treatment with a BCR-ABL inhibitor, e.g., IM, and a MEK inhibitor, e.g., trametinib.



traducir


 

COMBINATION THERAPY WITH DOUBLE NEGATIVE T-CELLS

NºPublicación: US2017071983A1 16/03/2017

Solicitante:
UNIV HEALTH NETWORK [CA]

Resumen de: US2017071983A1

There is provided herein methods of treating leukemia or lymphoma in a subject in need thereof, with double negative T cells (DNTs) in combination with Interferon-γ.



traducir


 

COMBINATION THERAPY FOR THE TREATMENT OF CANCER

NºPublicación: US2017071971A1 16/03/2017

Solicitante:
MCMASTER UNIV [CA]

Resumen de: US2017071971A1

Described are methods and compositions for treating cancer that include a dopamine receptor (DR) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a DNA synthesis inhibitor such as cytarabine or a microtubule inhibitor such as paclitaxel or docetaxel. The methods and compositions are useful for the treatment of cancers such as acute myeloid leukemia.



traducir


 

METHODS OF USING (+)-1,4-DIHYDRO-7-(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS

NºPublicación: AU2017201156A1 16/03/2017

Solicitante:
SUNESIS PHARMACEUTICALS INC

Resumen de: AU2017201156A1

Methods of treating, preventing or managing antecedent fematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment 5 using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.



traducir


 

Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies

NºPublicación: AU2015305449A1 16/03/2017

Solicitante:
CELGENE CORP

Resumen de: AU2015305449A1

Methods of treating, preventing and/or managing multiple myeloma are disclosed. Specific methods encompass the administration of an immunomodulatory compound,



traducir


 

Trophoblast glycoprotein (5T4, tpbg) specific chimeric antigen receptors for cancer immunotherapy

NºPublicación: AU2015310897A1 16/03/2017

Solicitante:
CELLECTIS

Resumen de: AU2015310897A1

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.



traducir


 

ANTI-LYMPHOMA PEPTIDES

NºPublicación: US2017073372A1 16/03/2017

Solicitante:
UNIV I TROMSO - NORGES ARKLISKE UNIV [SE]

Resumen de: US2017073372A1

The present invention provides a peptide which: (i) consists of 10 to 16 amino acids; (ii) has at least 8 cationic amino acids with either (a) a side chain comprising a guanidinium group, or (b) a side chain comprising an amino group, of which no more than 7 are consecutive; and (iii) has 2 or 3 tryptophan residues which are not both, or not all, consecutive, said peptide optionally in the form of a salt, ester or amide, or a peptidomimetic of said peptide. The invention further relates to pharmaceutical compositions containing these compounds, the use of these compounds in therapy, particularly as anti-tumour (e.g. anti-lymphoma) agents and non-therapeutic uses of these compounds.



traducir


 

METHODS OF TREATING MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA BY T CELL THERAPY

NºPublicación: WO2017044678A1 16/03/2017

Solicitante:
MEMORIAL SLOAN KETTERING CANCER CENTER [US]

Resumen de: WO2017044678A1

Disclosed herein are methods of treating multiple myeloma in a human patient in need thereof, comprising administering to the human patient a population of allogeneic cells comprising WT1-specific allogeneic T cells. Also disclosed herein are methods of treating plasma cell leukemia in a human patient in need thereof, comprising administering to the human patient a population of allogeneic cells comprising WT1-specific allogeneic T cells.



traducir


 

THERAPEUTIC AGENT OR TREATMENT METHOD FOR PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOCYTIC LEUKEMIA (ALL)

NºPublicación: WO2017042944A1 16/03/2017

Solicitante:
UNIV YAMANASHI [JP]
TOKAI UNIV EDUCATIONAL SYSTEM [JP]

Resumen de: WO2017042944A1

A pharmaceutical composition including a BCR-ABL tyrosine kinase inhibitor and a thalidomide derivative is provided as a result of the present invention. In addition, a method for treating Philadelphia chromosome-positive (Ph+) lymphocytic leukemia is provided that includes a step in which a BCR-ABL tyrosine kinase inhibitor and a thalidomide derivative are administered to a patient suffering from Philadelphia chromosome-positive (Ph+) lymphocytic leukemia.



traducir


 

THERAPEUTIC AGENT OR TREATMENT METHOD FOR PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOCYTIC LEUKEMIA (ALL) HAVING IKZF1 MUTATION

NºPublicación: WO2017043633A1 16/03/2017

Solicitante:
UNIV YAMANASHI [JP]
TOKAI UNIV EDUCATIONAL SYSTEM [JP]

Resumen de: WO2017043633A1

A pharmaceutical composition for treating Philadelphia chromosome-positive lymphocytic leukemia and including a BCR-ABL tyrosine kinase inhibitor and a thalidomide derivative is provided as a result of the present invention. In addition, a method for treating Philadelphia chromosome-positive lymphocytic leukemia is provided that includes a step in which a BCR-ABL tyrosine kinase inhibitor and a thalidomide derivative are administered to a patient suffering from Philadelphia chromosome-positive lymphocytic leukemia.



traducir


 

METHODS AND COMPOSITIONS FOR CANCER TREATMENT

Nº publicación: WO2017044701A1 16/03/2017

Solicitante:
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
WEILL MEDICAL COLLEGE OF CORNELL UNIV [US]

Resumen de: WO2017044701A1

A method for treating leukemia is disclosed. The method comprises administering to a subject with leukemia an effective amount of a pharmaceutical composition comprising a naked iron oxide nanoparticle, wherein the composition is not loaded with an active agent. Also disclosed is a method for treating cancer. The method comprises administering an effective amount of a pharmaceutical composition comprising a metal oxide nanoparticle comprising a polymeric coating over a metal oxide core, wherein the nanoparticle is loaded with a reactive oxygen species (ROS)-inducing agent.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver